Latest news with #analyst
Yahoo
2 hours ago
- Business
- Yahoo
Rockwell Stock Rises as Wall Street Firms Raise Price Targets
BofA Securities analyst Andrew Obin and Stephens analyst Tommy Moll both feel better about the outlook these days.
Wall Street Journal
3 days ago
- Business
- Wall Street Journal
Alcoa Posts Higher Second-Quarter Earnings Despite $115 Million in Aluminum Tariff Costs
Alcoa AA 0.25%increase; green up pointing triangle reported a higher second-quarter profit, topping analyst expectations, and said it mitigated U.S. aluminum tariff costs by redirecting Canadian aluminum to customers outside of the U.S. The Pittsburgh aluminum producer reported $164 million in net income, or 62 cents a share, up from $20 million, or 11 cents a share, from the prior year.
Globe and Mail
3 days ago
- Business
- Globe and Mail
Analysts Offer Insights on Energy Companies: Chord Energy (CHRD), PBF Energy (PBF) and Delek US Holdings (DK)
Companies in the Energy sector have received a lot of coverage today as analysts weigh in on Chord Energy (CHRD – Research Report), PBF Energy (PBF – Research Report) and Delek US Holdings (DK – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Chord Energy (CHRD) Wells Fargo analyst Hanwen Chang maintained a Buy rating on Chord Energy yesterday and set a price target of $143.00. The company's shares closed last Monday at $106.72, close to its 52-week low of $99.40. According to Chang is a 1-star analyst with an average return of -1.1% and a 45.6% success rate. Chang covers the NA sector, focusing on stocks such as Crescent Energy Company Class A, Magnolia Oil & Gas, and Matador Resources. ;'> Currently, the analyst consensus on Chord Energy is a Strong Buy with an average price target of $129.40, implying a 19.0% upside from current levels. In a report issued on June 30, RBC Capital also maintained a Buy rating on the stock with a $145.00 price target. PBF Energy (PBF) In a report released yesterday, Roger Read from Wells Fargo maintained a Hold rating on PBF Energy, with a price target of $24.00. The company's shares closed last Monday at $26.97. According to Read is a 3-star analyst with an average return of 0.9% and a 54.4% success rate. Read covers the NA sector, focusing on stocks such as Calumet Specialty Products, Liberty Oilfield Services, and HF Sinclair Corporation. ;'> PBF Energy has an analyst consensus of Moderate Sell, with a price target consensus of $20.00, a -28.6% downside from current levels. In a report issued on July 8, Morgan Stanley also maintained a Hold rating on the stock with a $20.00 price target. Delek US Holdings (DK) Bank of America Securities analyst Jean Ann Salisbury maintained a Sell rating on Delek US Holdings yesterday and set a price target of $13.00. The company's shares closed last Monday at $26.20. According to Salisbury is a 4-star analyst with an average return of 9.2% and a 65.2% success rate. Salisbury covers the NA sector, focusing on stocks such as Venture Global, Inc. Class A, Enterprise Products Partners, and Cheniere Energy Partners. ;'> The word on The Street in general, suggests a Hold analyst consensus rating for Delek US Holdings with a $18.00 average price target, a -32.0% downside from current levels. In a report issued on July 10, Morgan Stanley also maintained a Sell rating on the stock with a $15.00 price target.
Yahoo
4 days ago
- Business
- Yahoo
Why SoundHound AI (SOUN) Shares Are Falling Today
Shares of voice AI recognition company SoundHound (NASDAQ:SOUN) fell 4.5% in the morning session after the company received a downgrade from a Wall Street analyst. Piper Sandler adjusted its rating on the voice AI and conversational intelligence company from "Overweight" to "Neutral," citing concerns about the company's outlook for the second half of 2025. The firm noted that while SoundHound's long-term potential remains, there's a risk that some deals could be pushed into 2026. The analyst also highlighted the challenge SoundHound faces in trying to achieve profitability while investing in its product lines, suggesting that success could lead to higher earn-outs and share dilution. This more cautious stance comes despite Piper Sandler maintaining its $12 price target on the stock. The downgrade introduces a more balanced view on the company's near-term prospects, especially after the stock's significant run-up in recent months. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy SoundHound AI? Access our full analysis report here, it's free. SoundHound AI's shares are extremely volatile and have had 94 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. SoundHound AI is down 45.2% since the beginning of the year, and at $11.06 per share, it is trading 54.4% below its 52-week high of $24.23 from December 2024. Investors who bought $1,000 worth of SoundHound AI's shares at the IPO in April 2022 would now be looking at an investment worth $1,474. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Sign in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright
H.C. Wainwright lowered the firm's price target on Nurix Therapeutics (NRIX) to $34 from $36 and keeps a Buy rating on the shares. Nurix last week reported a Q2 net loss of (52c) per share, slightly narrower than the firm's previously estimated net loss of (62c) per share, the analyst tells investors in a research note. The firm is factoring in greater operating expenses moving forward. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NRIX: Disclaimer & DisclosureReport an Issue Top 3 Trending Stocks, According to Analysts – 7/11/2025 Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating
